Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

According to a study by Chevalier and colleagues, a single intra-articular ... knee OA at 12 weeks; the primary outcome of the study, therefore, was not met. However, significant short-term pain ...

DelveInsight's “Musculoskeletal Pain Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

The study’s primary objective is to assess the efficacy of a single intra-articular injection of 4P004 in reducing knee pain by week 4 and up to week 12. In addition, the study aims to assess ...

Osteoarthritis is a common chronic health condition that is characterised by joint pain and restricted movement. The main ...

Pacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...

Osteoarthritis (OA) of the knee is a progressive disease involving the intra-articular (IA) tibia-femoral and patella-femoral cartilage and all other surrounding IA and periarticular structures.1 It ...

Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug ...